Friday, 22 Jun 2018

You are here

The RheumNow Week in Review – Good News for GPA, CZP, Tofa but not ERA (6.1.18)

Dr. Jack Cush reviews this weeks reports from RheumNow.com, including the risk of autoimmunity with vaccination, early RA outcomes, new FDA approvals for certolizumab and tofacitinib and the risk of death from infection with biologics.

  1. UCB announces the FDA has approved Cimzia (certolizumab) for use in moderate to severe plaque psoriasis based on over 1000 pts in Phase 3 RCTs CIMPASI-1, CIMPASI-2 and CIMPACT and PASI75 of 75-82% at wk16. Certolizumab is now FDA approved for use in Crohns disease, Rheumatoid arthritis, Ankylosing spondylitis, psoriatic arthritis and now Psoriasis. https://t.co/PYx15htd3Z
  2. Pfizer announces that the FDA has approved Xeljanz (tofacitinib) 10 mg twice-daily (BID) for at least 8 Wks, followed by 5 mg BID or 10 mg BID, for adults with active ulcerative colitis (UC). This is 1st approval of 10mg bid dose https://t.co/z5hb5p8psF
  3. In RCTs, among 1157 ulcerative colitis pts receiving tofacitinib, 65 (5.6%) developed herpes zoster, 11 multidermatomal & 1 HZ encephalitis. HZ=4.07 with higher risk in elderly, Asians, prior TNFi failure & tofa 10 mg bid. http://bit.ly/2kEOjzH
  4. CMAJ reports on a Canadian population study of 290,939 girls 12–17 yrs who received quadravalent HPV vaccine with no increased risk of subsequent autoimmune disease (eg, Graves, Bells, JIA, SLE, AIHA, etc) https://t.co/jtJBDlE6jv
  5. US Renal Transplant system review ~20 yr data shows Renal transplantation results in a significant decrease (70%) in mortality among ESRD GPA patients, largely due to a 90% decrease in CVD death. https://t.co/vdWwGxJMvO 
  6. ESPOIR 5 Yr study of 403 early RA patients shows radiographic progression occurred in 143 (35.5%), more likely with high dose steroids and less likely with >36 mos of biologic therapy. https://t.co/onKuurpwZL 
  7. In a DMARD naive, early RA cohort (U-Act) study, 52% were MTX-IR at 1 year;  predictors of inadequate response to MTX included higher DAS28 (OR=2), current smoking (OR=3) and no alcohol consumption. https://t.co/FTxv5ZxObP
  8. British Biologics Registry of 19282 RA patients -the biologic SIE rate was 5.51 per 100 patient-yrs. The risk of death in the first 30days following a serious infection was 10% https://t.co/sIwd9S8QJM
  9. Increased Risk of Depression and Anxiety in Rheumatoid Arthritis  
  10. Cancer Risk Raised in Psoriatic Arthritis  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review – EULAR18 Epilogue (6.22.18)

Dr. Jack Cush reviews EULAR 2018 and the past week's news and reports from RheumNow.com, including DMARDs in OA, the price of Penicillamine, Infections when ANCA+, CV outcomes in gout, NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes.

CDC Obesity Prevalence Higher in the Rural USA

MMWR reports that approximately 46 million persons (14%) in the United States live in nonmetropolitan counties, where there is a higher prevalence of obesity-associated chronic diseases such as diabetes, coronary heart disease, and arthritis. (Citation source: http://bit.ly/2lj5yql)

EULAR 2018 - Podcast from Day 4

This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.

Click HERE to listen.

You can also listen on iTunes, Soundcloud or Stitcher.

EULAR 2018 - Podcast from Day 3

This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.

Click HERE to listen.

You can also listen on iTunes, Soundcloud or Stitcher. 

The RheumNow Week in Review – EULAR18 Abbreviated (6.15.18)

We're crazy busy at EULAR all week.  Instead of this review, we recommend that you tune into our multiple podcasts from experts and faculty attending EULAR 2018 in Amsterdam.  You can find these on iTunes, SoundCloud or Stitcher.

Tune in next week for the EULAR week in review!